Diet Induced Obesity Model for Cancer Research

A More Clinically Relevant Model to Uncover Your Treatment’s Potential

Obesity is a risk factor for at least 13 different forms of cancer. Mechanisms in which obesity and changes in systemic metabolism affect the tumor microenvironment (TME) and impact antitumor immunity are unclear. Current preclinical models use mouse strains which are fed a controlled diet and therefore host mice are not representative of Western human cancer populations. TD2 has established a diet induced obesity tumor model (Figure 1) to screen cancer therapies in a more clinically relevant system.

Figure 1: Establishment of diet induced obesity mouse tumor model

Benefits of Diet Induced Obesity Mouse Models:

Execute studies in more clinically relevant models reflective of the significant rates of obesity projected by 2035.
Understand how obesity induced systemic changes in metabolism effect the tumor microenvironment
Identify new treatments/mechanism of action that may show increased therapeutic benefit in DIO models
Quantify metabolite and proteomic changes in response to treatment that could be used as biomarkers of treatment benefit or as opportunity for new targets for drug development

Figure 2: Growth of subcutaneous MC38 model in C57BL6 mice (n=10) and
evaluation of anti-PD1 in DIO mice versus age matched Controlled Diet (CD) mice dosed Q3D x 4

Comprehensive
Preclinical Services

Regardless of the development question, TD2 has the specialized model you need to move your drug forward. Clients have access to humanized models, induction models, as well as specialty surgical and orthotopic models. We specialize in all areas of oncology and work diligently to understand your therapeutics’ mechanism of action. We match that with clinical development strategies for an efficient path forward.